- active not recruitingPHASE1, PHASE2
First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma
This study is testing a new medicine called epcoritamab for people with certain types of B-cell lymphoma that have come back or not responded to previous treatments. It aims to find the right dose, understand side effects, and see how well it works.
United States · Australia · Canada - recruitingPHASE2, PHASE3
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
This study is testing a new medicine, zilovertamab vedotin (ZV), combined with standard treatments for a type of lymphoma called diffuse large B-cell lymphoma (DLBCL). It's for people whose lymphoma has come back or hasn't responded to previous treatments.
United States · Argentina · Australia - recruitingPHASE1
Study of SGR-1505 in Mature B-Cell Neoplasms
This study is testing a new medicine called SGR-1505 for certain types of B-cell lymphoma. We want to find out if it's safe, what dose works best, and if it can help slow down the disease. It's for people whose treatment hasn't worked or stopped working.
United States · France · Italy - enrolling by invitationPHASE2
Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells
This study is checking on people who have had a special treatment called AUTO CAR T cell therapy. Doctors want to see how these patients are doing for up to 15 years after their treatment. This helps them understand the long-term effects of this new therapy for blood cancers.
United States · United Kingdom - recruiting
A Real-world Data and Sample Compendium of Frail and/or Multiply Treated Large B-cell Lymphoma
This study aims to understand how large B-cell lymphoma (LBCL) is treated in real life when standard treatments aren't suitable. We're looking at patients who are frail, or whose cancer has come back or didn't respond to initial treatment. This will help improve care for these patients.
United Kingdom